Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
Zacks.com on MSN1d
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Hosted on MSN1d
Nevro upgraded to Neutral from Underweight at Piper SandlerPiper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company ...
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback